Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors

NCT07043608 is registered in ClinicalTrials.gov with Kelly Fitzgerald, MD as lead sponsor.

NCT NCT07043608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07043608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors
Lead sponsor
Kelly Fitzgerald, MD
Phase
Phase 2
Overall status
Recruiting
Start date
June 10, 2026
Completion date
April 30, 2030
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases of a malignant tumor, bone, metastatic cancer, clear cell renal cancer, clear cell renal carcinoma, clear cell renal cell cancer (ccrcc), clear cell renal cell carcinoma, clear cell renal cell carcinoma metastatic, metastases to bone, metastatic cancer, metastatic renal cell carcinoma